4.87
+0.14(+2.96%)
Currency In USD
| Previous Close | 4.73 |
| Open | 4.79 |
| Day High | 4.88 |
| Day Low | 4.64 |
| 52-Week High | 12.4 |
| 52-Week Low | 3.5 |
| Volume | 198,928 |
| Average Volume | 544,288 |
| Market Cap | 299.55M |
| PE | 40.58 |
| EPS | 0.12 |
| Moving Average 50 Days | 4.53 |
| Moving Average 200 Days | 6.01 |
| Change | 0.14 |
If you invested $1000 in Monte Rosa Therapeutics, Inc. (GLUE) since IPO date, it would be worth $229.93 as of July 05, 2025 at a share price of $4.87. Whereas If you bought $1000 worth of Monte Rosa Therapeutics, Inc. (GLUE) shares 3 years ago, it would be worth $459.87 as of July 05, 2025 at a share price of $4.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
GlobeNewswire Inc.
Jul 03, 2025 6:15 PM GMT
Monte Rosa’s AI/ML-powered insights dramatically increase targetable protein space for molecular glue degraders, unlocking new opportunities to address previously undruggable therapeutic targets Science, 3 July 2025 Molecular Glue Computational min
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
GlobeNewswire Inc.
Jun 10, 2025 11:00 AM GMT
MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa’s clinical I&I portfolio Potency, selectivity, and long-lasting pha
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 28, 2025 11:00 AM GMT
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive